India, May 21, 2024 – Takeda Biopharmaceuticals India Pvt Ltd has announced the appointment of Annapurna Das as General Manager for its India operations.
According to the company’s statement, in her new role, Annapurna will lead the Company in India, ensuring patient access to its highly innovative medicines and vaccines, and advancing valuable collaborations to contribute to the growing domestic healthcare and pharmaceutical market.
“Annapurna comes with more than 20 years of experience in the pharmaceutical and biotechnology industry across India and Southeast Asia. Before joining Takeda, she held key leadership positions at various multinational healthcare companies, including Miltenyi Biotec, Sanofi, GSK, MSD, Pfizer and Organon, where she demonstrated exceptional leadership in sales, marketing, corporate strategy and business development across both pharma and vaccines businesses,” the company said in a statement.
“I am truly honoured to be entrusted with this responsibility by Takeda. India is one of the key countries for us, given its diverse population and the significant healthcare challenges. We are fully committed to serving patients in India by providing them with greater access to our innovative medicines and vaccines, ensuring they receive the best possible care. I look forward to working closely with our stakeholders and partners to strengthen our commitment in India while positively impacting the lives of patients across the country,” Annapurna Das said in a statement.
A part of Takeda Pharmaceutical Company Ltd headquartered in Japan, Takeda India specialises in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology etc., it stated.
“We are excited to welcome Annapurna to Takeda. Her vast experience and dedication to patient-focused solutions will fuel our continued success and growth in India. With her strategic leadership, we strive to positively impact patients’ lives with Takeda’s innovative healthcare solutions, and partnerships to broaden sustainable and equitable access to medicines and vaccines. Annapurna’s alignment with Takeda’s purpose and values reinforces our commitment to fostering a diverse and inclusive workplace, enabling us to create long-term value for patients and society. I am excited to partner with her to build on our strong foundation and take us to the next level of growth in India,” Dion Warren, Area Head of India and Southeast Asia, at Takeda said.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to people worldwide. The company focuses on innovative medicines for gastrointestinal and inflammation, rare diseases, plasma-derived therapies, and oncology.
In India, Takeda operates as Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.). The company focuses on Rare Diseases, including Hemophilia and Lysosomal Storage Disorders; Rare Immunology and specialty care for Gastroenterology and will soon be introducing its oncology portfolio in India.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
